BCAL Diagnostics Limited (BDX) Price & Analysis

Compare

7 Followers

BDX Stock Chart & Stats

AU$0.10

>-AU$0.01(-2.06%)

At close: Jan 09 4:00 PM EST

AU$0.10

>-AU$0.01(-2.06%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.16

Previous CloseN/A

Volume98.04K

Average Volume (3M)421.90K

Market Cap

AU$44.17M

Enterprise ValueAU$42.02M

Total Cash (Recent Filing)AU$4.52M

Total Debt (Recent Filing)AU$2.38M

Price to Earnings (P/E)―

Beta0.80

Next Earnings

Feb 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding368,067,630

10 Day Avg. Volume534,308

30 Day Avg. Volume421,904

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)3.64

Price to Sales (P/S)1047.06

P/FCF Ratio-3.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Manageable LeverageModerate leverage and a ~63% equity ratio provide structural financial flexibility. Lower debt reduces near-term refinancing risk and supports funding ongoing R&D and validation activities, extending runway compared with highly leveraged peers while commercialization options are developed.

Free Cash Flow CoverageA slightly positive free cash flow to net income ratio indicates some real cash generation relative to reported losses. This structural cash conversion can partially fund operations or trials, reducing immediate reliance on capital raises and helping sustain R&D and commercialization activities in the coming months.

Focused Diagnostics StrategyA clear strategic focus on blood-based breast cancer diagnostics targets a durable, high-need clinical market. If clinical validation and regulatory progress continue, the company benefits from persistent demand, differentiated IP and higher barriers to entry versus commodity diagnostics, supporting long-term revenue potential.

Bears Say

Severe Revenue DeclineA nearly total collapse in revenue is a structural red flag: it erodes scale needed for commercial launch, weakens pricing leverage, and undermines the firm's ability to fund validation and commercialization. Sustained low revenue materially increases financing and survival risk over months.

Deep UnprofitabilityVery large negative margins and operating losses show the business is not generating returns from operations. Combined with a negative ROE noted elsewhere, this undermines shareholder value creation and means the company must materially improve margins or secure external funding to reach a self-sustaining position.

Negative Operating Cash FlowNegative operating cash flow and declining free cash flow growth indicate cash burn that depletes resources and shortens runway. This structural cash-generation shortfall forces reliance on dilutive financing or partnerships, complicating long-term commercialization and making execution risk materially higher.

BCAL Diagnostics Limited News

BCAL Diagnostics Accelerates Commercial Rollout of Cancer Blood Tests and Targets Broader Market for BREASTESTplus

The latest update is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics has commenced the commercial...

12d ago

BDX

BCAL Diagnostics Ramps Up Cancer Test Launches as Clinical Data and Funding Strengthen Growth Plans

The latest update is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics has completed preparations for...

27d ago

BDX

BCAL Diagnostics to Launch Nationwide Cancer Detection Tests in Australia

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an announcement. BCAL Diagnostics Limited has announced the launch of...

2M ago

BDX

BCAL Diagnostics Launches Groundbreaking Breast Cancer Detection Test

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an update. BCAL Diagnostics Limited has achieved a significant milestone...

3M ago

BDX

BCAL Diagnostics Secures $2.5 Million R&D Tax Rebate for Cancer Detection Advancements

The latest announcement is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics Limited has received approximately...

3M ago

BDX

BCAL Diagnostics Director Increases Stake in Company

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an announcement. BCAL Diagnostics Limited has announced a change in...

3M ago

BDX

BCAL Diagnostics Schedules Annual General Meeting for November 2025

BCAL Diagnostics Limited ( ($AU:BDX) ) has shared an announcement. BCAL Diagnostics Limited has announced its Annual General...

4M ago

BDX

BCAL Diagnostics Schedules Annual General Meeting for 2025

The latest update is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics Limited has announced its...

4M ago

BDX

BCAL Diagnostics Announces Quotation of New Securities

BCAL Diagnostics Limited ( ($AU:BDX) ) has provided an update. BCAL Diagnostics Limited has announced the quotation of...

4M ago

BDX

BCAL Diagnostics Announces Convertible Debt Securities Issue

The latest update is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics Limited has announced a...

4M ago

BDX

BDX FAQ

What was BCAL Diagnostics Limited’s price range in the past 12 months?

BCAL Diagnostics Limited lowest share price was AU$0.05 and its highest was AU$0.15 in the past 12 months.

What is BCAL Diagnostics Limited’s market cap?

BCAL Diagnostics Limited’s market cap is AU$44.17M.

When is BCAL Diagnostics Limited’s upcoming earnings report date?

BCAL Diagnostics Limited’s upcoming earnings report date is Feb 18, 2026 which is in 2 days.

How were BCAL Diagnostics Limited’s earnings last quarter?

BCAL Diagnostics Limited released its earnings results on Aug 28, 2025. The company reported -AU$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.009.

Is BCAL Diagnostics Limited overvalued?

According to Wall Street analysts BCAL Diagnostics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BCAL Diagnostics Limited pay dividends?

BCAL Diagnostics Limited does not currently pay dividends.

What is BCAL Diagnostics Limited’s EPS estimate?

BCAL Diagnostics Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BCAL Diagnostics Limited have?

BCAL Diagnostics Limited has 368,067,630 shares outstanding.

What happened to BCAL Diagnostics Limited’s price movement after its last earnings report?

BCAL Diagnostics Limited reported an EPS of -AU$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of BCAL Diagnostics Limited?

Currently, no hedge funds are holding shares in AU:BDX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

BCAL Diagnostics Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-97.79%

Trailing 12-Months

Asset Growth

-19.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

BCAL Diagnostics Limited

BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.